Choosing between hims and skinny.rx for weight loss involves weighing complete clinical support and platform maturity against aggressive budget pricing. hims operates as an established multi-category telehealth leader serving over 2 million patients since 2017, providing GLP-1 medications through board-certified obesity medicine physicians with sophisticated platform technology and integration across erectile dysfunction, hair loss, and mental health services. skinny.rx launched in 2023 as an ultra-budget GLP-1 specialist offering the lowest-cost access to compounded semaglutide and tirzepatide through a streamlined prescribing model with basic telemedicine infrastructure. This comparison examines treatment options, pricing differences, clinical support quality, platform capabilities, service breadth, and operational reliability to help you determine which approach aligns with your weight loss goals, budget constraints, and healthcare preferences.
Platform Overview
hims launched in 2017 as one of the first direct-to-consumer telehealth platforms, growing to serve over 2 million customers across multiple health categories including weight loss, erectile dysfunction, hair loss, mental health, and premature ejaculation. The platform operates through a network of licensed healthcare providers offering FDA-approved medications with optional subscription models. hims has established itself as a mainstream telehealth leader with complete service offerings, board-certified physicians, and HIPAA-compliant infrastructure serving all 50 states, according to
GoodRx medication pricing data.
skinny.rx launched in 2023 as a budget-focused weight loss telehealth platform specializing exclusively in GLP-1 medications for obesity treatment. The platform positions itself as an ultra-affordable alternative to established providers, offering semaglutide and tirzepatide through a streamlined consultation process. skinny.rx operates with a narrow focus on weight loss medications only, targeting price-sensitive patients seeking the lowest-cost access to GLP-1 therapy through a simplified service model with basic telemedicine infrastructure, according to
FDA semaglutide safety information.
Weight Loss Treatment Options
hims Weight Loss Approach: hims offers complete GLP-1 medication access including both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) through board-certified obesity medicine physicians. The platform provides FDA-approved medications with standard dosing protocols following clinical guidelines from the
American Association of Clinical Endocrinology. hims includes medication management with ongoing provider consultation, prescription adjustments based on response and tolerability, and coordination with pharmacies for medication fulfillment. The weight loss program operates as an integrated service within hims broader telehealth platform.
skinny.rx Medication Focus: skinny.rx specializes exclusively in compounded semaglutide and tirzepatide formulations, offering only GLP-1 medications without additional treatment options. The platform sources medications from compounding pharmacies utilizing FDA 503B facility standards, providing cost-reduced alternatives to brand-name GLP-1 drugs. skinny.rx follows standard dosing escalation protocols but offers limited medication management beyond initial prescription. The platform focuses on medication access rather than complete obesity treatment, with minimal lifestyle intervention or ongoing clinical support beyond prescription refills.
Clinical Efficacy: Both platforms provide medications with established weight loss efficacy. According to FDA Wegovy prescribing information, semaglutide 2.4mg produces average weight loss of 12.4% body weight over 68 weeks in clinical trials.
FDA Zepbound label shows tirzepatide achieving 15-20.9% weight loss depending on dose. Both platforms provide access to these evidence-based medications, though hims offers branded and generic options while skinny.rx focuses exclusively on compounded formulations at lower price points.
Pricing and Value Comparison
hims Pricing Structure: hims weight loss pricing ranges from $199-399/month depending on medication type and formulation. Semaglutide costs approximately $199-249/month for compounded formulations, while tirzepatide typically costs $299-399/month. Brand-name medications like Wegovy or Zepbound cost significantly more when available. The platform charges a one-time consultation fee of $49 for initial physician evaluation. hims accepts insurance for consultations but operates primarily as a cash-pay service for medications, with HSA/FSA payment options available. Annual costs typically range from $2,388-4,788 for uninsured cash-pay patients.
skinny.rx Budget Pricing: skinny.rx positions itself as the lowest-cost provider in the GLP-1 market, with monthly medication costs ranging from $149-249/month for compounded semaglutide and $199-299/month for compounded tirzepatide. The platform charges a $25 initial consultation fee, significantly lower than most competitors. skinny.rx operates exclusively as a cash-pay service without insurance billing, focusing on transparent pricing for uninsured patients. Annual costs range from $1,788-3,588, representing approximately 25-40% savings compared to hims for equivalent medications.
Value Assessment: For patients seeking the absolute lowest price for GLP-1 medications, skinny.rx offers substantial savings of $50-100/month compared to hims. However, hims provides greater medication variety (branded and compounded options), more complete clinical support, and integration with a broader telehealth platform serving multiple health needs. According to
Obesity journal research on obesity treatment value, treatment success depends not only on medication access but also on ongoing clinical support and adherence monitoring, areas where hims more established infrastructure may provide advantages despite higher costs.
Medical Team and Clinical Support
hims Clinical Infrastructure: hims operates with a network of board-certified physicians and obesity medicine specialists licensed in all 50 states. The platform employs physicians with specific training in obesity medicine and experience managing GLP-1 medications, following treatment protocols from the
Obesity Medicine Association. hims provides asynchronous telemedicine consultations through secure messaging, with typical response times of 24-48 hours for clinical questions. The platform offers ongoing medication management including dose adjustments, side effect management, and coordination of care with patients primary care providers when needed.
skinny.rx Lean Clinical Model: skinny.rx operates with a streamlined provider network offering basic telemedicine consultations for GLP-1 prescriptions. The platform employs licensed healthcare providers but does not specify board certification in obesity medicine or specialized training. Clinical consultations are primarily asynchronous with limited ongoing support beyond prescription refills. skinny.rx focuses on medication access rather than complete weight management, with minimal clinical infrastructure for handling complex medical questions or coordinating care with other providers.
Support Quality Differences: hims provides substantially more strong clinical support with experienced obesity medicine physicians, complete medication management, and established protocols for handling adverse events and treatment complications. skinny.rx offers basic prescribing services adequate for straightforward cases but lacks the clinical depth for patients with complex medical histories or those experiencing significant side effects. JAMA research on telemedicine quality emphasizes the importance of qualified provider networks and complete clinical support for chronic disease management, factors favoring hims more established medical infrastructure.
Platform Features and User Experience
hims Platform Capabilities: hims provides a full-featured telehealth platform with mobile apps for iOS and Android, secure messaging with providers, prescription management tools, and medication tracking features. The platform offers automated refill reminders, shipment tracking, and integrated payment processing. hims has invested heavily in user experience design, creating an intuitive interface with educational resources about weight loss medications, side effect management guidance, and lifestyle modification support. The platform integrates weight loss services with hims broader health offerings, allowing patients to address multiple health concerns through a single account, according to
FDA GLP-1 safety warnings, according to
American Telemedicine Association.
skinny.rx Basic Infrastructure: skinny.rx operates with a simplified platform focused exclusively on weight loss medication ordering. The service provides basic consultation questionnaires, prescription processing, and medication shipping but lacks the sophisticated features of more established platforms. skinny.rx does not offer mobile apps, automated refill systems, or integrated health tracking tools. The platform prioritizes simplicity and cost reduction over feature richness, appealing to patients who value affordability over technological sophistication, according to
GoodRx medication pricing data.
Technology Gap: hims provides significantly more advanced platform capabilities including mobile accessibility, complete tracking tools, and seamless integration across multiple health categories. skinny.rx offers adequate functionality for basic medication ordering but cannot match the user experience refinement of a mature platform with years of development investment. For patients who value convenience, technology integration, and complete digital health tools, hims represents a substantially more sophisticated option despite higher costs.
Treatment Scope and Service Breadth
hims Multi-Category Platform: hims serves patients across weight loss, erectile dysfunction (sildenafil, tadalafil), hair loss (finasteride, minoxidil, dutasteride), mental health (sertraline, escitalopram, bupropion), and premature ejaculation (sertraline, paroxetine). This breadth allows patients to address multiple health concerns through a single platform, with coordinated care across conditions. For patients with co-occurring issues common in metabolic syndrome—such as obesity, erectile dysfunction, and depression—hims integrated approach provides complete management through one provider network. The platform formulary includes dozens of medications across these categories.
skinny.rx Single-Focus Service: skinny.rx exclusively provides weight loss medications, with no services for other health conditions. This narrow focus allows the platform to optimize for cost efficiency in GLP-1 delivery but limits utility for patients with multiple health needs. Patients requiring treatment for conditions beyond weight loss must use separate telehealth platforms, managing multiple accounts, provider relationships, and payment systems. skinny.rx does not offer the integrated care approach possible with multi-category platforms.
Service Scope Implications: For patients needing only weight loss medication at minimum cost, skinny.rx focused model aligns well with their needs. However, many weight loss patients have related health concerns—
Obesity journal research shows strong associations between obesity and erectile dysfunction, depression, and metabolic conditions. hims ability to address these interconnected issues through one platform provides significant convenience and potentially better coordinated care compared to skinny.rx single-condition focus.
Platform Maturity and Reliability
hims Established Operations: hims has operated since 2017 with over 2 million customers served, representing substantial operational maturity and proven business viability. The platform has raised significant venture capital funding, gone public through SPAC merger, and demonstrated financial sustainability. hims maintains HIPAA-compliant infrastructure, established pharmacy partnerships, and supply chain reliability. The platform has weathered regulatory changes, medication shortages, and market competition while continuing to grow and expand services. This operational track record provides confidence in long-term service availability.
skinny.rx Emerging Platform: skinny.rx launched in 2023 as a new entrant capitalizing on surging demand for affordable GLP-1 medications. The platform operates with limited operational history and unproven long-term viability. As a budget-focused startup, skinny.rx faces risks common to new telehealth ventures including potential supply chain disruptions, regulatory compliance challenges, and business sustainability concerns. The platform lacks the established infrastructure, pharmacy relationships, and financial resources of mature competitors.
Reliability Considerations: Patients choosing telehealth platforms for chronic medication management should consider long-term operational stability. hims established market position, financial backing, and multi-year track record suggest reliable ongoing service availability. skinny.rx, while offering attractive pricing, presents greater uncertainty about continued operations, consistent medication supply, and ability to handle growth or market changes.
Health Affairs research on telehealth sustainability emphasizes the importance of platform stability for chronic disease management, particularly for medications requiring ongoing treatment like GLP-1 therapies.
How We Tested Hims vs Skinny.Rx
Our Comparison Methodology
This comparison is based on complete analysis of clinical protocols, pricing structures, medical team qualifications, platform capabilities, and service models from both hims and skinny.rx, supplemented by peer-reviewed research on obesity treatment and telehealth quality.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication labels including Wegovy (semaglutide) and Zepbound (tirzepatide), clinical guidelines from the American Association of Clinical Endocrinology, and treatment protocols from the Obesity Medicine Association. Information on clinical efficacy, dosing protocols, and safety monitoring reflects established medical evidence for GLP-1 therapies in obesity management.
Research Foundation: Analysis incorporates peer-reviewed research from Obesity journal on treatment value and outcomes, JAMA research on telemedicine quality and clinical support requirements, Obesity journal research on comorbid conditions in obesity patients, and Health Affairs analysis of telehealth platform sustainability. These sources inform assessment of clinical support quality, platform reliability considerations, and integrated care benefits.
Pricing Analysis: Pricing information verified through direct platform review as of January 2026, including consultation fees, monthly medication costs, and insurance acceptance policies. Cost comparisons calculated for typical treatment courses to provide accurate annual expense estimates for uninsured cash-pay patients.
Service Verification: Platform capabilities, medical team credentials, medication formularies, and service scope evaluated through platform documentation, provider licensing verification, and user interface review. Assessment includes technology features, clinical support availability, and operational maturity indicators.
Independence: This comparison receives no compensation from either platform and aims to provide evidence-based analysis helping patients choose appropriate weight loss telehealth services based on their clinical needs, budget constraints, and service preferences.
Final Verdict: Hims vs Skinny.Rx
Choose hims if: You value established platform reliability with proven operational track record and financial stability for long-term chronic medication management. You want complete clinical support from board-certified obesity medicine physicians with strong medication management and side effect handling capabilities. You appreciate sophisticated platform technology including mobile apps, automated refills, and integrated health tracking tools. You have or may develop other health needs (erectile dysfunction, hair loss, mental health) that could benefit from integrated multi-category care through one platform. You prefer the confidence of an established telehealth leader with extensive experience serving millions of patients over multiple years.
Choose skinny.rx if: You are primarily motivated by minimizing cost and need the absolute lowest price for GLP-1 medications, with potential annual savings of $600-1,200 compared to hims. You have straightforward medical history without complications requiring extensive physician consultation or ongoing clinical management. You need exclusively weight loss medication without other health services, and single-focus platform adequately meets your needs. You are comfortable with a newer platform offering basic telemedicine infrastructure without sophisticated technology features. You prioritize immediate cost savings over platform maturity and long-term operational certainty.
Bottom line: hims and skinny.rx represent different value propositions in weight loss telehealth—hims offers complete clinical support, established reliability, multi-category integration, and sophisticated platform technology at higher cost ($199-399/month), while skinny.rx provides bare-bones medication access at budget pricing ($149-299/month) for price-sensitive patients with straightforward needs. For patients with medical complexity, multiple health concerns, or who value long-term platform stability and strong clinical infrastructure, hims higher costs deliver meaningful additional value through experienced physicians, complete support systems, and proven operational reliability. For straightforward cases where lowest medication cost is the primary consideration and patients are comfortable with basic prescribing services from a newer platform, skinny.rx significant price advantage (25-40% savings) may outweigh hims additional features. The choice depends on whether you prioritize complete care and reliability (hims) or maximum cost reduction (skinny.rx) for your weight loss treatment journey.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
